NasdaqGS:AMAG

Stock Analysis Report

Executive Summary

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States.

Rewards

Trading at 51.9% below its fair value

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway



Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has AMAG Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMAG has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.8%

AMAG

1.1%

US Biotechs

1.7%

US Market


1 Year Return

-30.6%

AMAG

11.5%

US Biotechs

23.2%

US Market

Return vs Industry: AMAG underperformed the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: AMAG underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

AMAGIndustryMarket
7 Day2.8%1.1%1.7%
30 Day-2.1%1.7%4.2%
90 Day5.7%21.5%11.9%
1 Year-30.6%-30.6%12.5%11.5%25.8%23.2%
3 Year-51.1%-51.1%29.3%25.1%52.8%42.9%
5 Year-74.7%-74.7%4.4%-0.5%75.2%55.8%

Price Volatility Vs. Market

How volatile is AMAG Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AMAG Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMAG ($12.19) is trading below our estimate of fair value ($25.35)

Significantly Below Fair Value: AMAG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMAG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AMAG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMAG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMAG is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is AMAG Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

56.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMAG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AMAG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AMAG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AMAG's revenue (2.8% per year) is forecast to grow slower than the US market (7.5% per year).

High Growth Revenue: AMAG's revenue (2.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMAG is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has AMAG Pharmaceuticals performed over the past 5 years?

-67.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMAG is currently unprofitable.

Growing Profit Margin: AMAG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMAG is unprofitable, and losses have increased over the past 5 years at a rate of -67.7% per year.

Accelerating Growth: Unable to compare AMAG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMAG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: AMAG has a negative Return on Equity (-59.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AMAG Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AMAG's short term assets ($340.8M) exceed its short term liabilities ($204.1M).

Long Term Liabilities: AMAG's short term assets ($340.8M) exceed its long term liabilities ($281.9M).


Debt to Equity History and Analysis

Debt Level: AMAG's debt to equity ratio (56.8%) is considered high.

Reducing Debt: AMAG's debt to equity ratio has reduced from 84.7% to 56.8% over the past 5 years.


Balance Sheet

Inventory Level: AMAG has a low level of unsold assets or inventory.

Debt Coverage by Assets: AMAG's debt is covered by short term assets (assets are 1.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMAG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AMAG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AMAG Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AMAG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AMAG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMAG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMAG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMAG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of AMAG Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Bill Heiden (59yo)

7.7yrs

Tenure

US$4,966,215

Compensation

Dr. William K. Heiden, also known as Bill, has been the Chief Executive Officer of AMAG Pharmaceuticals, Inc. since May 14, 2012 and serves as its President. Dr. Heiden serves as the Managing Director of V ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD4.97M) is above average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.1yrs

Average Tenure

47yo

Average Age

Experienced Management: AMAG's management team is considered experienced (4.1 years average tenure).


Board Age and Tenure

5.8yrs

Average Tenure

63yo

Average Age

Experienced Board: AMAG's board of directors are considered experienced (5.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$154,95213 Jan 20
Armistice Capital LLC
EntityCompany
Shares12,466
Max PriceUS$12.43
BuyUS$363,22613 Jan 20
Armistice Capital LLC
EntityCompany
Shares30,466
Max PriceUS$12.33
BuyUS$57,00004 Sep 19
Kenneth Shea
EntityIndividual
Shares5,000
Max PriceUS$11.40
BuyUS$39,082,01915 Aug 19
Caligan Partners, LP
EntityCompany
Shares3,449,428
Max PriceUS$11.33
BuyUS$2,200,40009 Aug 19
Armistice Capital LLC
EntityCompany
Shares300,000
Max PriceUS$7.43
BuyUS$3,029,79209 Aug 19
Camber Capital Management LLC
EntityCompany
Shares385,000
Max PriceUS$9.18
BuyUS$4,415,87727 Jun 19
Armistice Capital LLC
EntityCompany
Shares498,016
Max PriceUS$9.52
BuyUS$99,10029 May 19
Julie Krop
EntityIndividual
Role
Senior Key Executive
Executive VP of Clinical Development & Regulatory Affairs and Chief Medical Officer
Shares10,000
Max PriceUS$9.91
BuyUS$107,00009 May 19
William Heiden
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares10,000
Max PriceUS$10.70
BuyUS$54,65009 May 19
Elizabeth Bolgiano
EntityIndividual
Shares5,000
Max PriceUS$10.93

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Bill Heiden (59yo)

    CEO, President & Director

    • Tenure: 7.7yrs
    • Compensation: US$4.97m
  • Linda Lennox

    Vice President of Investor Relations & Corporate Communications

    • Julie Krop (53yo)

      Executive VP of Clinical Development & Regulatory Affairs and Chief Medical Officer

      • Tenure: 4.6yrs
      • Compensation: US$1.63m
    • Ted Myles (47yo)

      Executive VP

      • Tenure: 3.8yrs
      • Compensation: US$1.54m
    • Joseph Vittiglio (47yo)

      Executive VP of Legal Affairs and Quality

      • Tenure: 4.4yrs
      • Compensation: US$1.20m
    • Amit Verma

      Vice President of Marketing

      • Tenure: 6.5yrs
    • Tony Casciano (43yo)

      Executive VP & Chief Commercial Officer

      • Tenure: 3.3yrs
    • Laura Williams

      Senior Vice President of Clinical Development

      • Tenure: 2.3yrs
    • Tracy Berns

      Chief Compliance Officer

      • Tenure: 2.3yrs
    • Kelly Schick

      Senior VP & Chief Human Resources Officer


      Board Members

      • Jim Sulat (69yo)

        Independent Director

        • Tenure: 5.8yrs
        • Compensation: US$237.98k
      • Davey Scoon (72yo)

        Independent Director

        • Tenure: 13.1yrs
        • Compensation: US$254.98k
      • Bill Heiden (59yo)

        CEO, President & Director

        • Tenure: 7.7yrs
        • Compensation: US$4.97m
      • Rob Perez (55yo)

        Independent Director

        • Tenure: 11yrs
        • Compensation: US$229.98k
      • Barbara Deptula (64yo)

        Independent Director

        • Tenure: 6.3yrs
        • Compensation: US$240.98k
      • Gino Santini (62yo)

        Independent Chairman

        • Tenure: 5.8yrs
        • Compensation: US$282.98k
      • John Fallon (71yo)

        Independent Director

        • Tenure: 5.3yrs
        • Compensation: US$247.48k
      • Anne Phillips (65yo)

        Independent Director

        • Tenure: 0.8yrs
      • David Johnson (37yo)

        Independent Director

        • Tenure: 0.3yrs
      • Kathrine O’Brien (57yo)

        Independent Director

        • Tenure: 0.8yrs

      Company Information

      AMAG Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: AMAG Pharmaceuticals, Inc.
      • Ticker: AMAG
      • Exchange: NasdaqGS
      • Founded: 1981
      • Industry: Biotechnology
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: US$401.563m
      • Shares outstanding: 33.92m
      • Website: https://www.amagpharma.com

      Number of Employees


      Location

      • AMAG Pharmaceuticals, Inc.
      • 1100 Winter Street
      • Waltham
      • Massachusetts
      • 2451
      • United States

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      AMAGNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1986
      AMUDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1986

      Biography

      AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company’s products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/18 00:02
      End of Day Share Price2020/01/17 00:00
      Earnings2019/09/30
      Annual Earnings2018/12/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.